Compare GVH & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | SILO |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Apparel |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 3.1M |
| IPO Year | 2023 | 2011 |
| Metric | GVH | SILO |
|---|---|---|
| Price | $0.92 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.8K | ★ 30.0K |
| Earning Date | 07-14-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | $1.85 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $1.10 |
| 52 Week High | $6.46 | $10.43 |
| Indicator | GVH | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 34.34 |
| Support Level | $0.87 | $1.10 |
| Resistance Level | $1.13 | $4.80 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 46.95 | 39.39 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.